<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29196" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sodium Bicarbonate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Senewiratne</surname>
            <given-names>Niluk Leon</given-names>
          </name>
          <aff>University of California Riverside School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Woodall</surname>
            <given-names>Allison</given-names>
          </name>
          <aff>UCR/Riverside Community Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Can</surname>
            <given-names>Ahmet S.</given-names>
          </name>
          <aff>Lake Erie College of Osteopathic Medicine (LECOM)</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Niluk Leon Senewiratne declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Allison Woodall declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmet Can declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29196.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sodium bicarbonate is a multifaceted medication that plays a crucial role in managing and treating diverse disease pathologies. This activity delves into the expansive applications of sodium bicarbonate, providing healthcare professionals with a nuanced understanding of its indications, mechanism of action, and contraindications. The program focuses on its pivotal role in treating conditions such as lactic acidosis and QRS prolongation, offering participants in-depth insights into therapeutic considerations, including dosing, toxicities, and relevant interactions. By examining sodium bicarbonate's adverse event profile, participants will be better equipped to ensure its effective utilization across a spectrum of clinical scenarios. This evidence-based activity aims to empower interprofessional healthcare team members with the essential knowledge to optimize sodium bicarbonate's potential to enhance patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify clinical scenarios and biochemical abnormalities where sodium bicarbonate is indicated while considering evidence-based guidelines.</p></list-item><list-item><p>Differentiate between FDA-approved and non-FDA-approved uses of sodium bicarbonate while understanding the clinical evidence supporting each application.</p></list-item><list-item><p>Assess the effects of sodium bicarbonate while promptly evaluating for therapeutic responses and identifying any toxic changes or adverse reactions.</p></list-item><list-item><p>Identify&#x000a0;sodium bicarbonate therapy's indications, benefits, and potential risks while ensuring informed decision-making with patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29196&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29196">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29196.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Sodium bicarbonate&#x000a0;is a chemical compound&#x000a0;comprising sodium (Na<sup>+</sup>) and bicarbonate (HCO3<sup>-</sup>), with numerous indications.</p>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute or chronic metabolic acidosis related to:
<list list-type="bullet"><list-item><p>Severe renal disease</p></list-item><list-item><p>Uncontrolled diabetes</p></list-item><list-item><p>Severe primary lactic acidosis&#x000a0;<xref ref-type="bibr" rid="article-29196.r1">[1]</xref><xref ref-type="bibr" rid="article-29196.r2">[2]</xref><xref ref-type="bibr" rid="article-29196.r3">[3]</xref></p></list-item><list-item><p>Circulatory insufficiency due to shock</p></list-item><list-item><p>Severe dehydration</p></list-item><list-item><p>Extracorporeal circulation of blood</p></list-item><list-item><p>Cardiac arrest</p></list-item><list-item><p>Drug toxicity</p></list-item><list-item><p>Barbiturates</p></list-item><list-item><p>Toxic alcohols&#x000a0;<xref ref-type="bibr" rid="article-29196.r4">[4]</xref></p></list-item><list-item><p>Urine alkalization&#x000a0;<xref ref-type="bibr" rid="article-29196.r5">[5]</xref></p></list-item><list-item><p>Severe diarrhea with HCO<sub>3</sub><sup>-</sup> loss</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Urinary alkalinization</p>
          </list-item>
          <list-item>
            <p>Dyspepsia
<list list-type="bullet"><list-item><p>Oral sodium bicarbonate is approved to relieve&#x000a0;heartburn, acid indigestion, and upset stomach associated with these symptoms, and is available over the counter (eg, baking soda, effervescent granules).<xref ref-type="bibr" rid="article-29196.r6">[6]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved Indication ("Off-label" uses)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nebulized sodium bicarbonate is an excellent option for treating chemical injuries from chlorine gas, especially within the pulmonary mucosa; it is believed that the inhaled gas neutralizes when it reacts with water and bicarbonate within the respiratory system.<xref ref-type="bibr" rid="article-29196.r7">[7]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tricyclic antidepressant overdose resulting in QRS prolongation&#x000a0;<xref ref-type="bibr" rid="article-29196.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Cardiac conduction delays</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29196.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bicarbonate is often a standard element of body fluids and is often regulated by the kidney via secretion or absorption methods to counter-regulate changes in serum pH. This action often leads to its second administration as it is known to alkalinize the urine, capable of changing precipitants in urine and providing a means of normalizing tubular acid concentration gradients to manage high fluctuations in serum acid-base status changes. This alkalization process enables compounds that would normally precipitate in the renal tubules in acidic conditions to be buffered within the renal tubule, thereby preventing mechanical or chemical damage while also providing increased efficiency within the kidney tubules to excrete acidified substances without disrupting the electrochemical gradient.<xref ref-type="bibr" rid="article-29196.r9">[9]</xref><xref ref-type="bibr" rid="article-29196.r4">[4]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>After administration, intravenous sodium bicarbonate dissociates to&#x000a0;form sodium (Na<sup>+</sup>) and bicarbonate (HCO<sub>3</sub><sup>-</sup>) ions. Bicarbonate anions can consume hydrogen ions (H) and&#x000a0;subsequently convert to carbonic acid (H<sub>2</sub>CO<sub>3</sub>). Carbonic acid subsequently converts to water (H<sub>2</sub>O) and carbon dioxide (CO<sub>2</sub>)&#x000a0;for excretion from the lungs. The main therapeutic effect of intravenous sodium bicarbonate administration is increasing plasma bicarbonate levels, which buffer excess hydrogen ion (H<sup>+</sup>)concentration, raising serum pH to combat clinical manifestations of acidosis.</p>
        <list list-type="order">
          <list-item>
            <p>Absorption:&#x000a0;Following oral administration, excess bicarbonate is absorbed, resulting in metabolic alkalosis and alkalinization of urine. IV administration results in complete bioavailability.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Distribution:&#x000a0;Sodium bicarbonate is widely distributed in the extracellular fluid.</p>
          </list-item>
          <list-item>
            <p>Metabolism: Sodium bicarbonate has an unknown half-life.</p>
          </list-item>
          <list-item>
            <p>Excretion:&#x000a0;Bicarbonate is excreted in the urine; it is excreted and reabsorbed by the kidneys. Bicarbonate is also transported to the lungs&#x000a0;and exhaled as carbon dioxide.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29196.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms and Strengths</bold>
</p>
        <p>NaHCO<sub>3</sub> comes in various forms, including oral tablets, IV injections, and IV infusions. Oral formulations are available via 325 mg powder and 650 mg oral tablets. One mEq NaHCO<sub>3</sub> is 84 mg. One gram of NaHCO<sub>3</sub> contains 11.9 mEq of sodium and bicarbonate ions. One 650 mg tablet of NaHCO<sub>3</sub> has 7.7 mEq of sodium and bicarbonate ions.</p>
        <p>The&#x000a0;2 primary IV injection formulations of NaHCO<sub>3</sub> are:</p>
        <list list-type="bullet">
          <list-item>
            <p>7.5% concentration = 44.6 mEq NaHCO<sub>3</sub> in 50 mL. This concentration supplies 75 mg/mL of 0.9 mEq/mL each of sodium and bicarbonate.</p>
          </list-item>
          <list-item>
            <p>8.4% concentration = 50 mEq in 50 mL. This concentration supplies 84 mg/mL of 1 mEq/mL for each sodium and bicarbonate. One ampoule of 50 mL contains 50 mEq sodium and 50 mEq bicarbonate to a total of 100 mEq/50 mL and corresponds to 2000 mOsm/L. This formulation is a hypertonic solution that can raise serum sodium concentration by attracting water to the extracellular areas from the intracellular space.</p>
          </list-item>
          <list-item>
            <p>A 4.2% and 5% solution are also available, though not as often used.&#x000a0;</p>
          </list-item>
        </list>
        <p>NaHCO<sub>3</sub> IV infusions are&#x000a0;available in the following formulations:</p>
        <list list-type="bullet">
          <list-item>
            <p>50 mEq, 75 mEq, 100 mEq NaHCO<sub>3</sub> in 1L of 0.45% NS, 0.45% NS+D5W, or D5W</p>
          </list-item>
          <list-item>
            <p>50 mEq, 75 mEq, 100 mEq, and 150 mEq NaHCO<sub>3</sub> in 1L D5W or sterile water</p>
          </list-item>
          <list-item>
            <p>Bicarbonate tablets are available as 650 mg NaHCO<sub>3</sub>, 25&#x000a0;to 50 mEq KHCO<sub>3</sub>, 20&#x000a0;to 40 mEq KHCO<sub>3</sub>-citric acid, and 20&#x000a0;to 50 mEq KHCO<sub>3</sub>-KCl tablets.<xref ref-type="bibr" rid="article-29196.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>In patients with arrhythmias and cardiovascular instability, sodium bicarbonate can be administered to adults&#x000a0;with 4&#x000a0;to 8-hour IV infusions. Each dose should be monitored and planned in a standard protocol to help evaluate the degree of response expected and predicted to understand the necessity to advance further infusions or withhold administration, given its fluid overloading effects.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Acute metabolic acidosis:</bold>&#x000a0;2 to 5 mEq/kg/dose IV for a single dose; subsequent dosing based on patient response and acid-base status.</p>
        <p>
<bold>Chronic metabolic acidosis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic renal failure: 1625 to 2925 mg/day orally divided every 4 to 6 hours; dose adjustments are based on serum HCO<sub>3</sub> levels.</p>
          </list-item>
          <list-item>
            <p>Distal renal tubular acidosis:&#x000a0;48&#x000a0;to&#x000a0;168 mg/kg/day orally divided every 4 to 6 hours; dose adjustments are based on serum HCO<sub>3</sub>&#x000a0;levels.</p>
          </list-item>
          <list-item>
            <p>Proximal&#x000a0;renal tubular acidosis:&#x000a0;420 to&#x000a0;840 mg/kg/day orally divided every 4 to 6 hours; dose adjustments are based on serum HCO<sub>3</sub>&#x000a0;levels.</p>
          </list-item>
        </list>
        <p><bold>Lactic acidosis:</bold> Using sodium bicarbonate remains controversial but is an option if pH is below 7.<xref ref-type="bibr" rid="article-29196.r11">[11]</xref></p>
        <p>Diabetic ketoacidosis: The use of sodium bicarbonate remains controversial in diabetic ketoacidosis since recovery outcomes are similar with or without NaHCO3. However, if the pH is below 7 after 1 hour of fluid administration, sodium bicarbonate is still recommended. Sodium bicarbonate should be given in hypotonic fluid every&#x000a0;2 hours until pH is 7 or higher.<xref ref-type="bibr" rid="article-29196.r12">[12]</xref></p>
        <p><bold>Salicylate overdose:</bold> 1 to 2 mEq/kg/dose IV for a single dose</p>
        <p>Hyperkalemia: When patients with severe hyperkalemia (serum potassium level of more than 6 mEq/L or more than 5.5 mEq/L with arrhythmia or EKG changes) have metabolic acidosis, sodium bicarbonate should be administered. The dose needed is empirical and unpredictable. Initially, 150 mEq of sodium bicarbonate can be given in 1 liter of 5% dextrose over 4 hours. More can be provided if acidosis is not corrected with this regimen.<xref ref-type="bibr" rid="article-29196.r13">[13]</xref>&#x000a0;If there is a need to decrease serum potassium emergently, 50 mEq of NaHCO3 IV can be given over 5 minutes, followed by other methods of potassium reduction.</p>
        <p>Urinary alkalinization: 975 to 1950 mg orally every 4 hours, starting with 3900 mg orally for a single dose</p>
        <p><bold>Dyspepsia:</bold> varies with age</p>
        <list list-type="bullet">
          <list-item>
            <p>For those younger than 60: 650 to 2600 mg should be taken orally every 4 hours to a maximum of 15.6 g/d.</p>
          </list-item>
          <list-item>
            <p>Age 60&#x000a0;years and older:&#x000a0;650 to 1300 mg orally every 4 hours as needed to a maximum of&#x000a0;7.8 g/d.</p>
          </list-item>
        </list>
        <p><bold>Cardiac arrest:</bold> Currently, routine bicarbonate administration for cardiac arrest is no longer a recommendation.&#x000a0;The agent should only be administered for cardiac arrest due to hyperkalemia, tricyclic antidepressant overdose, or metabolic acidosis.<xref ref-type="bibr" rid="article-29196.r14">[14]</xref> Dosing is 1 mEq/kg per dose, repeated according to arterial blood gas measurements. Sodium bicarbonate should ideally be given after adequate alveolar ventilation and the initiation of cardiac compressions.</p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hepatic impairment</bold>: Dosing in patients with hepatic impairment is undefined.</p>
          </list-item>
          <list-item>
            <p><bold>Renal impairment</bold>: Dosing in renal impairment is undefined; however, clinicians should exercise caution as the drug may cause sodium retention. Dosing in dialysis is undefined.</p>
          </list-item>
          <list-item>
            <p><bold>Pregnancy Considerations</bold>:<bold>&#x000a0;</bold>Clinicians should weigh the risks and benefits when considering sodium bicarbonate during pregnancy, as comprehensive human data is unavailable. There is a potential risk of fluid retention based on the drug's mechanism.</p>
          </list-item>
          <list-item>
            <p><bold>Breastfeeding Considerations</bold>:<bold>&#x000a0;</bold>No human data are available to assess the risk of fetal harm or affecting milk production.</p>
          </list-item>
          <list-item>
            <p><bold>Pediatric patients:&#x000a0;</bold>Rapidly injecting (10 mL/min) of hypertonic sodium bicarbonate into neonates and children younger than 2&#x000a0;may&#x000a0;cause hypernatremia,&#x000a0;decreased cerebrospinal fluid pressure, and possible intracranial hemorrhage. The administration rate in pediatric patients should be limited to 8 mEq/kg/d. A 4.2% solution may be preferable&#x000a0;for such slow administration. In emergent situations&#x000a0;like cardiac arrest, the risk accompanying rapid infusion must be weighed against the potential for fatality due to acidosis.</p>
          </list-item>
          <list-item>
            <p><bold>Older patients:&#x000a0;</bold>Clinical studies of sodium bicarbonate have had insufficient numbers of subjects 65 and older to determine&#x000a0;whether they respond differently than younger subjects. Additionally, reported clinical experience has not identified different responses between&#x000a0;older and younger patients. Clinicians should generally exercise caution in dosing sodium bicarbonate in older patients, typically starting at the lower end of the dosing range.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29196.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Sodium bicarbonate can result in a multitude of adverse effects, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic alkalosis</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Muscle pain and twitching</p>
          </list-item>
          <list-item>
            <p>Nausea or vomiting</p>
          </list-item>
          <list-item>
            <p>Bradypnea</p>
          </list-item>
          <list-item>
            <p>Nervousness or restlessness</p>
          </list-item>
          <list-item>
            <p>Unpleasant taste</p>
          </list-item>
          <list-item>
            <p>Increased frequency of urination</p>
          </list-item>
          <list-item>
            <p>Tissue damage/necrosis secondary to extravasation&#x000a0;<xref ref-type="bibr" rid="article-29196.r15">[15]</xref><xref ref-type="bibr" rid="article-29196.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>Administration and extravasation of sodium bicarbonate have been known to cause chemical cellulitis due to its basic properties and have resulted in tissue necrosis, ischemia, and tissue death at administration sites.&#x000a0;</p>
        <p>In significant dose administrations, it is known to increase edema and is more commonly noted in those with renal insufficiency, given its clearance via the kidneys.&#x000a0;This increase in tissue edema appears to be due to an excess hyperosmolar state developed during the administration of sodium bicarbonate, resulting in fluid retention. This condition can be especially challenging to manage in those with underlying cardiovascular comorbidities, including those with heart failure and intravascular fluid management difficulties.&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Certain IV additives may be incompatible; norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.</p>
        <p>The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except&#x000a0;in instances where compatibility has&#x000a0;already been established. Sodium bicarbonate/calcium admixtures may result in precipitation or hazing.&#x000a0;The injection should not be used if&#x000a0;precipitate is present.</p>
        <p>Due to its ability to buffer pH and influence acid-base shifts, sodium bicarbonate can also affect many drug-drug interactions, including fluoroquinolones such as levofloxacin and tetracyclines such as doxycycline and minocycline.&#x000a0;These effects are often noted in oral preparations where both medications are taken orally and result in significantly decreased GI absorption due to compound structural alterations due to changes in pH in the GI lumen,&#x000a0;such as NSAIDs, mesalamine, and also with extended-release formulations (eg, methylphenidate).&#x000a0;</p>
        <p>Other&#x000a0;interactions are due to the effects of sodium bicarbonate on increasing renal tubular pH, thereby increasing passive tubular reabsorption and increasing serum levels of medications such as dextroamphetamine and methamphetamine.</p>
      </sec>
      <sec id="article-29196.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Due to rapid alkalotic effects, sodium bicarbonate is contraindicated in those with signs/symptoms or laboratory values indicating underlying metabolic or respiratory alkalosis due to the potential for exacerbation of symptoms.&#x000a0;Another contraindication is for those who have hypersensitivity to sodium bicarbonate injections.<xref ref-type="bibr" rid="article-29196.r4">[4]</xref><xref ref-type="bibr" rid="article-29196.r16">[16]</xref></p>
        <p>Secondary to deionizing effects on metabolically active ionized serum calcium, sodium bicarbonate is contraindicated in&#x000a0;patients with hypocalcemia. The administration of sodium bicarbonate can also exacerbate hypernatremia.</p>
        <p>Rapid or high-dose administration of undiluted sodium bicarbonate may lead to decreased CSF pressure and intracranial hemorrhage, particularly in the pediatric population younger than 2.<xref ref-type="bibr" rid="article-29196.r17">[17]</xref></p>
      </sec>
      <sec id="article-29196.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Clinicians should monitor serum electrolytes such as calcium, urinary pH, and when indicated, arterial blood gases. In metabolic acidosis, the acid-base balance should be monitored.<xref ref-type="bibr" rid="article-29196.r18">[18]</xref></p>
      </sec>
      <sec id="article-29196.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Rapid administration of sodium bicarbonate may increase intravascular fluid volume, leading to acute pulmonary edema. Additionally, the medication must be administered judiciously in those with congestive heart failure, significant renal disease, or sodium retention due to exacerbation of sodium retention and edema.</p>
        <p>Sodium bicarbonate administration in a rapid infusion or as large boluses can result in acute metabolic alkalosis, reducing serum ionized calcium. This acute shift in ionized calcium can result in tetany. The accompanying alkalosis is treatable with ammonium chloride. Hypocalcemia may be addressed with calcium gluconate. An addition of 0.9% NS infusion and potassium supplementation may also be indicated.<xref ref-type="bibr" rid="article-29196.r19">[19]</xref><xref ref-type="bibr" rid="article-29196.r20">[20]</xref></p>
      </sec>
      <sec id="article-29196.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Appropriate&#x000a0;use of sodium bicarbonate and preventing its potential adverse effects require the involvement of the allied interprofessional team of healthcare professionals. When ordering sodium bicarbonate for a patient, the clinician, nursing team, and pharmacy team must recognize the indications for the medication and observe any toxicity or adverse effects from its administration. Clinicians need to ensure that sodium bicarbonate is the appropriate therapeutic choice. Nursing staff will either administer the drug for inpatients or give instructions for home administration for outpatient use and counsel regarding potential adverse events. Pharmacists will verify appropriate dosing, perform medication reconciliation checking for drug-drug interactions, and reinforce patient counseling points where applicable.&#x000a0;</p>
        <p>Utilizing an interprofessional team approach to sodium bicarbonate therapy will increase the chances of therapeutic success while minimizing adverse events, resulting in better patient outcomes. Consistent clinical observation and recognition at the bedside consistently improve morbidity and mortality&#x000a0;by reducing medication errors, medication-induced reactions, and&#x000a0;adverse effects.&#x000a0;</p>
      </sec>
      <sec id="article-29196.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29196&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29196">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29196/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29196">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29196.s11">
        <title>References</title>
        <ref id="article-29196.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adeva-Andany</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Fern&#x000e1;ndez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mouri&#x000f1;o-Bayolo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Castro-Quintela</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dom&#x000ed;nguez-Montero</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Sodium bicarbonate therapy in patients with metabolic acidosis.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>627673</fpage>
            <pub-id pub-id-type="pmid">25405229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lutterman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Adriaansen</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>van 't Laar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of severe diabetic ketoacidosis. A comparative study of two methods.</article-title>
            <source>Diabetologia</source>
            <year>1979</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">38163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arieff</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Indications for use of bicarbonate in patients with metabolic acidosis.</article-title>
            <source>Br J Anaesth</source>
            <year>1991</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-77</page-range>
            <pub-id pub-id-type="pmid">1653584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirrakhimov</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ayach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barbaryan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Talari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chadha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions.</article-title>
            <source>Int J Nephrol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>7831358</fpage>
            <pub-id pub-id-type="pmid">28932601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erejuwa</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Aja</surname>
                <given-names>DOJ</given-names>
              </name>
              <name>
                <surname>Uwaezuoke</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Nwadike</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Ezeokpo</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Akpan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Nwobodo</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Araromi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Asika</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effects of honey supplementation on renal dysfunction and metabolic acidosis in rats with high-fat diet-induced chronic kidney disease.</article-title>
            <source>J Basic Clin Physiol Pharmacol</source>
            <year>2020</year>
            <month>May</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">32396139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maton</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>855</fpage>
            <page-range>855-70</page-range>
            <pub-id pub-id-type="pmid">10400401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cevik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Onay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akmaz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sezigen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mass casualties from acute inhalation of chlorine gas.</article-title>
            <source>South Med J</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>102</volume>
            <issue>12</issue>
            <fpage>1209</fpage>
            <page-range>1209-13</page-range>
            <pub-id pub-id-type="pmid">20016425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradberry</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Thanacoody</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Watt</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Management of the cardiovascular complications of tricyclic antidepressant poisoning : role of sodium bicarbonate.</article-title>
            <source>Toxicol Rev</source>
            <year>2005</year>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-204</page-range>
            <pub-id pub-id-type="pmid">16390221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pentel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benowitz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and mechanism of action of sodium bicarbonate in the treatment of desipramine toxicity in rats.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1984</year>
            <month>Jul</month>
            <volume>230</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-9</page-range>
            <pub-id pub-id-type="pmid">6086872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spivey</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Lathers</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McNamara</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Schoffstall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tumer</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Comparison of intraosseous, central, and peripheral routes of sodium bicarbonate administration during CPR in pigs.</article-title>
            <source>Ann Emerg Med</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>1135</fpage>
            <page-range>1135-40</page-range>
            <pub-id pub-id-type="pmid">2998236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Walley</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Is there a role for sodium bicarbonate in treating lactic acidosis from shock?</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-83</page-range>
            <pub-id pub-id-type="pmid">18614899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiasson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Aris-Jilwan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>B&#x000e9;langer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beauregard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eko&#x000e9;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Havrankova</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state.</article-title>
            <source>CMAJ</source>
            <year>2003</year>
            <month>Apr</month>
            <day>01</day>
            <volume>168</volume>
            <issue>7</issue>
            <fpage>859</fpage>
            <page-range>859-66</page-range>
            <pub-id pub-id-type="pmid">12668546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abuelo</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Severe Hyperkalemia: Confronting 4 Fallacies.</article-title>
            <source>Kidney Int Rep</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-55</page-range>
            <pub-id pub-id-type="pmid">29340313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velissaris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karamouzos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pierrakos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koniari</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Apostolopoulou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Karanikolas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Use of Sodium Bicarbonate in Cardiac Arrest: Current Guidelines and Literature Review.</article-title>
            <source>J Clin Med Res</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-83</page-range>
            <pub-id pub-id-type="pmid">26985247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Solh</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Abou Jaoude</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Porhomayon</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bicarbonate therapy in the treatment of septic shock: a second look.</article-title>
            <source>Intern Emerg Med</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-7</page-range>
            <pub-id pub-id-type="pmid">20169423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00141;oniewski</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wesson</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Bicarbonate therapy for prevention of chronic kidney disease progression.</article-title>
            <source>Kidney Int</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>529</fpage>
            <page-range>529-35</page-range>
            <pub-id pub-id-type="pmid">24107852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Shehri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alqahtani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alromih</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Altamimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alshehri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Almehaideb</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jabari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alzayed</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The practices of intravenous sodium bicarbonate therapy in neonatal intensive care units: A multi-country survey.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2023</year>
            <month>Jul</month>
            <day>21</day>
            <volume>102</volume>
            <issue>29</issue>
            <fpage>e34337</fpage>
            <pub-id pub-id-type="pmid">37478246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sep&#x000fa;lveda</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Juanet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Intravenous sodium bicarbonate. When, how and why to use it?].</article-title>
            <source>Rev Med Chil</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>150</volume>
            <issue>9</issue>
            <fpage>1214</fpage>
            <page-range>1214-1223</page-range>
            <pub-id pub-id-type="pmid">37358132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Role of magnesium in the risk of intradialytic hypotension among maintenance hemodialysis patients.</article-title>
            <source>Hemodial Int</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>351</fpage>
            <page-range>351-358</page-range>
            <pub-id pub-id-type="pmid">32395903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29196.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bose</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cytotoxic and osteogenic effects of crocin and bicarbonate from calcium phosphates for potential chemopreventative and anti-inflammatory applications in vitro and in vivo.</article-title>
            <source>J Mater Chem B</source>
            <year>2020</year>
            <month>Mar</month>
            <day>11</day>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>2048</fpage>
            <page-range>2048-2062</page-range>
            <pub-id pub-id-type="pmid">32064472</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
